A Multicenter, Open Label, Phase I/Randomized II Study to Evaluate Safety, Pharmacokinetics and Efficacy of BIBF 1120 in Comparison With Sorafenib for Advanced Hepatocellular Carcinoma Patients in Asia.
Phase of Trial: Phase I/II
Latest Information Update: 01 Jul 2017
At a glance
- Drugs Nintedanib (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 02 Jun 2015 Pooled analysis results of this and another trial (NCT01004003; 1199-37) presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 24 Apr 2014 Planned End Date changed from 1 Oct 2014 to 1 Jun 2014, as per ClinicalTrials.gov record.
- 19 Feb 2014 Planned End Date changed from 1 Mar 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History